In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia
Andrew King(The Pirbright Institute), Bryan F. Cox(Abbott Fund), Gang Zhao(Sichuan University), Scott W. Mittelstadt(Abbott Fund), Philip R. Kym(AbbVie (United States)), Regina M. Reilly(Abbott (United States)), Kelly J. Larson(Abbott Fund), Christine A. Collins(AbbVie (United States)), Martin J. Voorbach(AbbVie (United States)), Jason A. Segreti(Abbott Fund), Andrew J. Souers(AbbVie (United States))
Cited by 37
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
|Proceedings of the National Academy of Sciences|2002|415